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(-)-Epigallocatechin-3-gallate (EGCG) maintains k-casein in its pre-fibrillar state 
without redirecting its aggregation pathway 
Abstract 
The polyphenol (-)-epigallocatechin-3-gallate (EGCG) has recently attracted much research interest in the 
field of protein-misfolding diseases because of its potent anti-amyloid activity against amyloid-beta, 
alpha-synuclein and huntingtin, the amyloid-fibril-forming proteins involved in Alzheimer's, Parkinson's and 
Huntington's diseases, respectively. EGCG redirects the aggregation of these polypeptides to a disordered 
off-folding pathway that results in the formation of non-toxic amorphous aggregates. whether this anti-
fibril activity is specific to these disease-related target proteins or ismore generic remains to be 
established. In addition, the mechanism by which EGCG exerts its effects, as with all anti-amyloidogenic 
polyphenols, remains unclear. To address these aspects, we have investigated the ability of EGCG to 
inhibit amyloidogenesis of the generic model fibril-forming protein RCMkappa-CN (reduced and 
carboxymethylated kappa-casein) and thereby protect pheochromocytoma-12 cells from RCMkappa-CN 
amyloid-induced toxicity. We found that EGCG potently inhibits in vitro fibril formation byRCMkappa-CN 
[the IC50 for 50 uM RCMkappa-CN is 1 uM]. Biophysical studies reveal that EGCG prevents RCMkappa-CN 
fibril formation by stabilising RCMkappa-CN in its nativelike state rather than by redirecting its 
aggregation to the disordered, amorphous aggregation pathway. Thus, while it appears that EGCG is a 
generic inhibitor of amyloid-fibril formation, the mechanism by which it achieves this inhibition is specific 
to the target fibril-forming polypeptide. It is proposed that EGCG is directed to the amyloidogenic sheet-
turn-sheet motif of monomeric RCMkappa-CN with high affinity by strong non-specific hydrophobic 
associations. Additional non-covalent pi-pi stacking interactions between the polyphenolic and aromatic 
residues common to the amyloidogenic sequence are also implicated. 
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The polyphenol (−)-epigallocatechin-3-gallate (EGCG) has recently attracted
much research interest in the field of protein-misfolding diseases because of
its potent anti-amyloid activity against amyloid-β, α-synuclein and
huntingtin, the amyloid-fibril-forming proteins involved in Alzheimer's,
Parkinson's and Huntington's diseases, respectively. EGCG redirects the
aggregation of these polypeptides to a disordered off-folding pathway that
results in the formation of non-toxic amorphous aggregates. Whether this
anti-fibril activity is specific to these disease-related target proteins or ismore
generic remains to be established. In addition, the mechanism by which
EGCG exerts its effects, as with all anti-amyloidogenic polyphenols, remains
unclear. To address these aspects, we have investigated the ability of EGCG
to inhibit amyloidogenesis of the generic model fibril-forming protein
RCMκ-CN (reduced and carboxymethylated κ-casein) and thereby protect
pheochromocytoma-12 cells from RCMκ-CN amyloid-induced toxicity. We
found that EGCGpotently inhibits in vitro fibril formation by RCMκ-CN [the
IC50 for 50 μMRCMκ-CN is 13±1 μM]. Biophysical studies reveal that EGCG
prevents RCMκ-CN fibril formation by stabilising RCMκ-CN in its native-
like state rather than by redirecting its aggregation to the disordered,
amorphous aggregation pathway. Thus, while it appears that EGCG is a
generic inhibitor of amyloid-fibril formation, the mechanism by which it
achieves this inhibition is specific to the target fibril-forming polypeptide. It
is proposed that EGCG is directed to the amyloidogenic sheet–turn–sheet
motif of monomeric RCMκ-CN with high affinity by strong non-specific
hydrophobic associations. Additional non-covalent π–π stacking interac-
tions between the polyphenolic and aromatic residues common to the
amyloidogenic sequence are also implicated.
© 2009 Elsevier Ltd. All rights reserved.
Edited by K. Kuwajima
Keywords: amyloid fibril; κ-casein; polyphenol; (−)-epigallocatechin-3-gallate;
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Introduction
Protein-misfolding diseases encompass over 40
debilitating and incurable human conditions asso-
ciated with the failure of a specific peptide or protein
to adopt or remain in its native functional state.1
These conditions include pathologies as diverse as
Alzheimer's disease, Parkinson's disease, cataract
and type II diabetes.1 The majority of misfolding
diseases are associated with amyloidosis.1,2 This
pathological state involves the aggregation of
specific polypeptides into highly stable and cyto-
toxic filamentous deposits known as amyloid fibrils,
which comprise a characteristic core of cross-β-sheet
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john.carver@adelaide.edu.au.
Present address: H. Ecroyd, School of Biological
Sciences, University of Wollongong, Wollongong, New
South Wales 2522, Australia.
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dynamic light scattering; EGCG, (−)-epigallocatechin-3-
gallate; MTT, methylthiazolyldiphenyl-tetrazolium
bromide; NBT, nitroblue tetrazolium; PC12,
pheochromocytoma-12; RCMκ-CN, reduced and
carboxymethylated κ-casein; TEM, transmission electron
microscopy; ThT, thioflavin T; TOCSY, total correlated
spectroscopy; a.u., arbitrary units.
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structure.1–3 As the number of people suffering from
amyloidosis is increasing rapidly in developed
countries, due to longer average life expectancies,
understanding the aggregation process and know-
ing how to prevent amyloid-fibril formation have
become major challenges.2
Fig. 1. EGCG inhibits RCMκ-CN amyloid-fibril formation. (a) The structure of the EGCG. (b) In situ ThT fluorescence
assay of RCMκ-CN (50 μM) incubated at 37 °C in the presence and in the absence of EGCG. A solution of EGCG (50 μM)
without RCMκ-CNwas also monitored (control). Values shown are the mean readings from three individual experiments,
and the standard errors for each data point are within 4% (not visible). Inset plot shows the fitted logarithmic
concentration–response (percentage of protection) curve (variable slope model) for calculating the IC50. All percentage-of-
protection data points are significantly different (Pb0.05, one-way ANOVA, Bonferroni's post hoc test, n=3). (c–e) TEM
micrographs of samples from the in situ ThT fluorescence assay: (c) fresh native RCMκ-CN prior to incubation, (d) RCMκ-
CN alone after incubation and (e) RCMκ-CN in the presence of EGCG (50 μM) after incubation. Bars represent 200 nm. (f)
Time-resolved DLS analysis of RCMκ-CN (50 μM) incubated at 37 °C. The particle diameter-intensity distribution profiles
are shown at selected time points. (g) Time-resolved DLS analysis of RCMκ-CN (50 μM)with and without EGCG at 37 °C.
The mean hydrodynamic diameter of particles is plotted.
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There is currently no approved therapeutic agent
directed toward amyloid fibrils or fibril precursors.
Yet, over the past 5 years, a wide range of com-
pounds have been found to prevent fibril formation,
reverse fibrillation and protect against amyloid-
fibril-associated cytotoxicity.4–11 These compounds
target the various stages in the life cycle of an
amyloidogenic protein, including stabilising the
native state, inhibiting the enzymes that process
proteins into amyloidogenic peptides, altering pro-
tein synthesis and increasing the clearance of
misfolded proteins by stimulating protein quality
control systems.4,5,12 However, most prominent is
the development of small-molecule drug candidates,
termed anti-aggregates, which selectively interact
with the aggregating polypeptides and inhibit or
reverse the formation of toxic amyloid fibrils and
pre-fibrillar entities.5,7–10
Natural polyphenolics comprise over 8000 plant-
derived compounds found in high concentrations in
wine, tea, spices, berries and a wide variety of other
plants.8 They are characterised by the presence of
more than one phenol group per molecule.8 These
compounds constitute one of the most potent classes
of anti-aggregation agents known to date.8–10,13,14 In
addition to their anti-amyloidogenic properties,
these molecules possess potent anti-oxidant activity
and a number of other beneficial health effects, such
as anti-carcinogenic, anti-viral and anti-inflamma-
tory properties.8,15 Recently, (−)-epigallocatechin-3-
gallate (EGCG) (Fig. 1a), the most abundant poly-
phenolic extract from green tea, has been under
extensive investigation after emerging evidence
suggested that it may improve glucose metabolism,
lipid metabolism and endothelial function and
reduce the effects of arthritis, neurodegenerative
diseases, hypertension, coronary heart disease,
obesity, inflammation, cancer and insulin resis-
tance.15–24 Furthermore, this multifunctional poly-
phenol drastically reduces cognitive impairment and
amyloid deposition in Alzheimer's transgenic
mice.25–27 Biochemical studies indicate that the
neuroprotective action of EGCG results from its
ability to inhibit protein aggregation, suppress/
enhance amyloidogenic/non-amyloidogenic proteo-
lytic processes, scavenge free radicals, chelate iron
and co-modulate various other cellular pathways.28–33
In acting as an anti-aggregate, EGCG efficiently
inhibits the amyloid-fibril formation of α-synuclein,
amyloid-β and huntingtin, the amyloidogenic pro-
teins involved in Parkinson's, Alzheimer's and
Huntington's diseases, respectively.34,35 EGCG
directly binds to the natively unfolded polypeptides
and redirects their aggregation down an off-folding
pathway, resulting in the formation of unstructured,
innocuous and highly stable oligomers.34,35 How-
ever, detailed understanding of the interaction
between amyloidogenic polypeptides and EGCG, or
any other polyphenols for that matter, remains
elusive due to the difficulties associated with
biophysical characterisation of non-covalent interac-
tions (especially involving large macromolecular
assemblies). Moreover, while the anti-amyloid-fibril
activity of EGCG has been shown against some
disease-related proteins and peptides, it remains to
be established whether this activity is specific to
these target proteins or is a more generic action that
may have application in the treatment of other
amyloid-fibril-associated diseases.
To address these issues, we have investigated the
effect of EGCG on RCMκ-CN (reduced and carbox-
ymethylated κ-casein), the non-disease-associated
amyloid-fibril-forming protein, with which we have
considerable experience. RCMκ-CN serves as an
excellent model to study generic aspects of fibril
formation and its inhibition as it is easily prepared
from the bovine milk protein, κ-casein, and forms
amyloid fibrils reproducibly in a short time frame
under conditions of physiological temperature and
pH and without the need for denaturants.36,37 The
resulting amyloid fibrils are also cytotoxic (F.C.D. et
al., unpublished results). Native RCMκ-CN exists in
a self-associating equilibrium between monomers
and spherical micelle-like oligomers.38 It is the
monomeric species that is believed to account for
the highly amyloidogenic nature of RCMκ-CN since,
although ‘natively disordered’ in structure (similar
to all caseins), its putative central ‘horse-and-rider’
conformation contains a large hydrophobic and
aromatic-rich repeated sheet–turn–sheet motif that
acts as a template to form the fibril core.36,39,40
Herein, we show that EGCG is an efficient
inhibitor of RCMκ-CN fibril formation and its
associated cytotoxicity, suggesting that EGCG has
generic anti-aggregation activity. Our biophysical
studies indicate that the mechanism bywhich EGCG
inhibits fibril formation by RCMκ-CN is through the
constraint of the protein in its native-like state rather
than by redirecting its aggregation to the disordered
(amorphous) pathway. Thus, our results indicate
that the mode by which EGCG exerts its anti-
amyloid-fibril activity may vary depending on the
target species.
Results
EGCG potently inhibits RCMκ-CN amyloid-fibril
formation by maintaining the protein in its
native-like state
First, to determine the anti-aggregation efficacy of
EGCG toward RCMκ-CN, we performed a standard
in situ thioflavin T (ThT) fluorescence assay using
RCMκ-CN (50 μM) in the presence and in the
absence of EGCG (1–100 μM) at 37 °C (Fig. 1b). As
we have previously reported, the initial decrease in
ThT fluorescence during the first 30 min of incuba-
tion is attributable to the samples' warming to the
incubation temperature.36 The ThT fluorescence of
RCMκ-CN alone increases rapidly after the equili-
bration period and reaches a plateau after 800–
1000 min, which is indicative of amyloid-fibril
formation.36,37 Incubation of RCMκ-CN with
EGCG leads to a concentration-dependent decrease
in the ThT fluorescence, with 50 μMEGCG (i.e., a 1:1
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molar ratio) yielding complete mitigation. By calcu-
lating the percentage of protection from the ThT
curve of RCMκ-CN alone and fitting a logarithmic
concentration–response curve, the EGCG concentra-
tion that gives 50% inhibition of the increase in ThT
fluorescence (IC50, value±standard error of fit) was
13±1 μM (Fig. 1b, inset). Furthermore, EGCG
incubated alone (Fig. 1b, control) produced no
change in ThT fluorescence over the course of in-
cubation, indicating that EGCG is neither inherently
amyloidogenic nor likely to interact directly with
free solvated ThT.
The morphological effects of EGCG (50 μM) on
RCMκ-CN (50 μM) fibril formation were assessed
simultaneously by transmission electron micro-
scopy (TEM) (Fig. 1c–e). In agreement with our
previous studies, TEM micrographs of RCMκ-CN
taken before fibril formation indicate that RCMκ-CN
exists initially as globular micelle-like species with a
diameter of ∼30 nm (Fig. 1c).37 However, at the
plateau region (post-incubation), most available pre-
fibrillar entities have been incorporated into mature
amyloid fibrils (Fig. 1d). Moreover, in accordance
with the ThT assay, the presence of EGCG (at a 1:1
molar ratio) inhibits fibrillation entirely and gives
rise to RCMκ-CN species (Fig. 1e) with morphology
that is typical of oligomers and early pre-fibrillar
assemblies (F.C.D. et al., unpublished observations).
To corroborate the findings of the ThT and TEM
experiments, we monitored RCMκ-CN (50 μM)
fibril formation at 37 °C in the presence and in the
absence of EGCG (10 and 50 μM) directly by
dynamic light scattering (DLS) (Fig. 1f and g). DLS
allows the hydrodynamic diameter of particles in
solution to be measured.41 The particle diameter
distribution of RCMκ-CN alone shifts from a peak
centred at ∼30 nm to ∼75 nm over the period of
incubation (Fig. 1f). This growth, shown in real time
by mean hydrodynamic diameter measurements
(Fig. 1g), has dynamics similar to that of the in situ
ThT data and implies that both the ThT assay and
the DLS techniques are monitoring the same
aggregation processes. Furthermore, akin to the
ThT binding assay, particle growth in the presence
of EGCG is suppressed by 20% and 100% at 1:0.2
and 1:1 RCMκ-CN:EGCG molar ratios, respectively.
Therefore, on the basis of the ThT, TEM and DLS
analyses, it appears that EGCG mitigates RCMκ-CN
amyloidogenesis by constraining the protein in its
micellar native-like state, constituting species such as
monomers, oligomers and early pre-fibrillar inter-
mediates. Furthermore, assuming a direct RCMκ-
CN–EGCG interaction, and since RCMκ-CN fibrilla-
tion is prevented so efficiently by EGCG (e.g., ∼85%
inhibition at 1:0.5 RCMκ-CN/EGCG), it is plausible
that a single EGCG molecule interacts with multiple
RCMκ-CN species concurrently and that RCMκ-CN
has multiple sites for EGCG interaction.
EGCG binds strongly to RCMκ-CN via
intermolecular hydrophobic interactions
Proteins that have been separated by SDS-PAGE
and electroblotted onto nitrocellulose or polyviny-
lidene fluoride membrane can be selectively stained
with nitroblue tetrazolium (NBT) to identify pro-
tein-bound quinone and quinonoid-related sub-
stances, such as polyphenols.34,42,43 Here, we
employed this technique to investigate the binding
action and selectivity of EGCG. Samples of freshly
prepared native RCMκ-CN (50 μM) and bovine
serum albumin (BSA) (10 μM) in the presence and in
the absence of EGCG (10–100 μM) were separated
by SDS-PAGE (Fig. 2a). BSAwas used as a standard
hydrophobic test protein.34 The bands were then
electroblotted onto polyvinylidene fluoride mem-
brane and stained with NBT (Fig. 2b). The presence
of EGCG does not affect electrophoretic migration,
Fig. 2. EGCG binds to BSA and RCMκ-CN. (a) SDS-PAGE analysis of BSA (10 μM) or native RCMκ-CN (50 μM) in the
presence and in the absence of EGCG. Ratios above the lanes indicate the molar ratio between protein and EGCG for each
sample. The weak bands represent minor protein impurities and are not a result of adding EGCG. (b) NBT staining assay
of electroblotted polyvinylidene fluoride membrane of (a).
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and the major protein bands appear at their
expected positions (i.e., ∼66 and ∼19 kDa for BSA
and RCMκ-CN, respectively).34,36,44 The NBT colour
reaction occurs for all protein bands from samples
containing EGCG. Colorimetric image analysis
shows that there is a 1.4-fold increase in formazan
stain intensity between the bands of 1:1 and 1:2
protein/EGCG. From these data, it is concluded that
EGCG potentially binds to more than one site on
each of the proteins. The EGCG–protein association
is also sufficiently strong to survive the reducing
and denaturing conditions of SDS-PAGE. Moreover,
in view of the common hydrophobicity of BSA,
RCMκ-CN and EGCG,37,40,44–48 and since the
hydrophobic regions of proteins are readily exposed
under SDS-PAGE conditions,49 these results suggest
that a non-specific non-covalent hydrophobic inter-
action mediates EGCG binding to these proteins.
EGCG prevents the time-dependent changes in
the secondary structure of RCMκ-CN
Circular dichroism (CD) spectroscopy was em-
ployed to investigate the effect of EGCG binding on
RCMκ-CN secondary structure. The far-UV CD
spectra of RCMκ-CN (10 μM) with and without
EGCG (2–10 μM) were acquired before and after
incubation at 37 °C for 40 h to allow for fibril
formation and the inhibition thereof (Fig. 3). Native
RCMκ-CN alone gives a spectrum with a maximum
negative mean residue ellipticity at 200 nm and a
shoulder between 213 and 230 nm, which is
indicative of a predominantly random coil structure
and is in accordance with the CD spectra of RCMκ-
CN reported previously.36,40 Following incubation,
the maximum negative mean residue ellipticity at
Fig. 4. EGCG interacts with the
inflexible regions of RCMκ-CN.
One-dimensional 1H NMR spectra
of fresh native RCMκ-CN (250 μM)
in deuterated sodium phosphate
buffer (50 mM, pH 7.4) with and
without EGCG recorded at 25 °C.
The comparative EGCG (50 μM)
spectrum is also shown. The few
sharp resonances in the RCMκ-CN
spectra (at ∼2.0, 3.3 and 3.7 ppm)
arise from low-molecular-weight
impurities. In the presence of
RCMκ-CN, the aromatic resonances
of EGCG (at 6.7 and 7.0 ppm,
arrows) are only just observed with
10-fold molar excess of EGCG.
Resonance intensities for each spec-
trum are not relative.
Fig. 3. The changes in secondary structure of RCMκ-
CN are prevented by EGCG. Far-UV CD spectra of RCMκ-
CN (10 μM) before incubation (0 h) and following
incubation at 37 °C for 40 h in the presence and in the
absence of EGCG.
693Anti-Aggregation Activity of EGCG
200 nm is increased and red-shifted to 204 nm and
the shoulder between 213 and 230 nm is also
increased in negative ellipticity, in agreement with
our previous findings.36 These changes are indica-
tive of a small loss of random coil and an increase in
β-sheet content, which are consistent with the
proposal that RCMκ-CN exists with well-positioned
β-sheet backbone and thus requires little conforma-
tional change to aggregate.36,40 In the presence of
EGCG, the generation of β-sheet that accompanies
RCMκ-CN fibril formation is suppressed and
RCMκ-CN seemingly does not undergo any changes
in secondary structure (Fig. 3). This effect is
concentration dependent in accordance with the
anti-aggregation efficacy of EGCG (Fig. 1b, inset).
Thus, these findings corroborate the evidence that
EGCG inhibits the aggregation pathway by stabilis-
ing RCMκ-CN in its native-like state.
EGCG interacts with inflexible regions of
RCMκ-CN with high affinity as monitored by
1H NMR spectroscopy
To further elucidate the non-covalent binding
action of EGCG, we recorded one-dimensional 1H
and two-dimensional total correlated spectroscopy
(TOCSY) NMR spectra of freshly prepared native
RCMκ-CN (250 μM) with and without EGCG (250
and 2500 μM) (Fig. 4; representative and non-
redundant TOCSY spectra are presented in the
Supplementary Material). The corresponding NMR
spectra of EGCG alone (50 μM) were also acquired
(Fig. 4). The extensive overlap and lack of chemical
shift dispersion of RCMκ-CN NMR resonances are
consistent with the relatively unstructured and
highly flexible nature of RCMκ-CN.36,39,40 Titration
of RCMκ-CN with equimolar or 10-fold molar
excess of EGCG does not lead to the loss or shift of
the observed RCMκ-CN resonances or cross-peaks,
implying that the conformational flexibility of
RCMκ-CN is maintained upon interaction with
EGCG and that EGCG does not interact significantly
with the flexible regions of RCMκ-CN. Furthermore,
since the inflexible (more rigid) regions of mono-
meric RCMκ-CN are proposed to encompass the
highly amyloidogenic sheet–turn–sheet motif,36,40
EGCG may be directly targeting the amyloidogenic
sequence of RCMκ-CN.
The EGCG resonances are broadened significantly
when EGCG is in the presence of RCMκ-CN. Even at
a 10-fold molar excess, the intense aromatic reso-
nances of EGCG (at 6.7 and 7.0 ppm in the one-
dimensional 1H NMR spectrum) are only just
observed (Fig. 4). This finding affirms that EGCG is
likely to interact with the more rigid regions of
RCMκ-CN, thereby increasing its overall correlation
time such that its resonances broaden out. Moreover,
this observation suggests that EGCG has a high
affinity for RCMκ-CN (i.e., resonances of EGCG are
not observed because most EGCG is bound to
RCMκ-CN). Alternatively, the association–disasso-
ciation exchange rate may be intermediate on the
NMR timescale, and thus the observed EGCG
resonances are broadened out due to a combination
of broad and sharp resonances, corresponding to
EGCG bound to and that unbound to RCMκ-CN,
respectively.
In a second experiment, one-dimensional 1H and
two-dimensional TOCSY NMR spectra of RCMκ-
CN (250 μM) with and without EGCG (250 and
2500 μM) were recorded after the reaction mixtures
had been incubated at 37 °C for 20 h. For all samples,
there was no significant difference from the compar-
able spectra acquired prior to incubation under the
fibril-forming conditions (Fig. 4; representative
TOCSY data in the Supplementary Material). This
implies that there is little structural reconfiguration
when RCMκ-CN is sequestered into amyloid fibrils.
The flexible regions of RCMκ-CN are thus main-
tained and must remain exterior to the rigid internal
cross-β-sheet amyloid core. We have observed
similar behaviour during fibril formation by the
small heat-shock protein, αB-crystallin, whereby the
C-terminal extension of the protein remains flexible,
Fig. 5. The real-time interaction between RCMκ-CN and EGCG by NMR spectroscopy. (a and b) The change in
intensity of various resonances from real-time 1H NMR spectra acquired every 5 min for samples of RCMκ-CN (50 μM) in
deuterated sodium phosphate buffer (50 mM, pH 7.4) incubated at 37 °C in the absence (a) and in the presence (b) of
EGCG (50 μM). The negative change in ThT fluorescence of RCMκ-CN (50 μM) is overlaid on (a) to showmatching trends
between the resonance decay and fibril growth. All profiles of intensity for each sample are not statistically different.
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protruding from the fibrillar core.50 This finding
is consistent with the evidence that RCMκ-CN
fibril formation occurs through simple sequestra-
tion and stacking of the structurally constrained
β-sheet region of monomeric RCMκ-CN, with
little conformational change necessary to facilitate
amyloidogenesis.36,40 However, over the period of
incubation, there is a small decrease in resonance
intensity of all RCMκ-CN resonances in the absence
of EGCG, as discussed below.
Real-time NMR spectroscopy of the interaction
between EGCG and RCMκ-CN
The subtle changes in resonance intensities of the
RCMκ-CN 1H NMR resonances were monitored by
real-time 1H NMR spectroscopy. Samples of RCMκ-
CN (50 μM) with and without EGCG (50 μM) were
incubated at 37 °C, one-dimensional 1H NMR
spectra were acquired every 5 min and the change
in resonance intensity with time was determined
(Fig. 5). For RCMκ-CN alone, all resonance decay
profiles are essentially identical and occur with the
same time constant as the change in ThT fluorescence
associated with the formation of amyloid fibrils (Fig.
5a), which implies that they are monitoring the same
process. The loss of resonance intensity of the
observed flexible RCMκ-CN resonances is consistent
with a loss of their conformational flexibility.
However, the loss of flexibility is small and uniform
(i.e., it is not selective for any particular resonances),
corroborating that the mobile regions of RCMκ-CN
retain their highly flexible nature in the amyloid
structure and that the loss of resonance intensity
results primarily from the incorporation of RCMκ-
CN into slow-tumbling high-molecular-weight
fibrillar assemblies. Interestingly, during the first
60 min of incubation, the loss of resonance intensity
is small and is similar to the lag time observed in the
overlaid ThT experiment. This period most likely
corresponds to the initial period of fibrillation, where
RCMκ-CN is aggregating to form small non-fibrillar
species, such as oligomers, nuclei and protofibrils,
which are not large enough to cause an observable
loss in resonance intensity.
In the presence of EGCG, the relative resonance
intensities remain mostly unaltered over the period
of incubation (Fig. 5b), indicating that amyloidogen-
esis and the corresponding loss of flexibility of
RCMκ-CN are prevented by EGCG and that the
interaction of EGCG with RCMκ-CN occurs early
along the latter's aggregation profile. Furthermore,
this result is consistent with the evidence that EGCG
suppresses RCMκ-CN fibril formation by interact-
ing with the inflexible amyloidogenic β-sheet region
of RCMκ-CN and thereby keeps RCMκ-CN in its
native-like non-fibrillar state.
EGCG protects against RCMκ-CN
amyloid-induced cytotoxicity
Finally, to assess the cytoprotective capacity of
EGCG, we treated pheochromocytoma-12 (PC12)
cells with RCMκ-CN pre-incubated at 37 °C for 20 h
with and without EGCG from the in situ ThT
fluorescence assay (see Fig. 1b). The final concentra-
tion of RCMκ-CN was 0.5 μM. Following incubation
of the treated cells for 48 h, cellular survival was
measured by methylthiazolyldiphenyl-tetrazolium
bromide (MTT) reduction (Fig. 6). Treatment with
EGCG alone does not affect cell survival. Significant
protection from amyloid-associated toxicity is
observed when EGCG is present at concentrations
higher than 0.05 μM. The effective EGCG concentra-
tion that gives 50% cytoprotection (EC50, value±
standard error of fit) is 0.17±0.05 μM. Accounting
for the 1/100 dilution of the samples when adding
them to the cell culture medium, this value is in
excellent agreement with the IC50 for the inhibition
of RCMκ-CN fibril formation by EGCG in vitro as
determined by ThT fluorescence (i.e., 13±1 μM) (Fig.
1b). Hence, these data indicate that the suppression
of RCMκ-CN fibril formation by EGCG in vitro
results in direct attenuation of its cytotoxic effects.
Discussion
In this study, we have investigated the effect of
EGCG on the model non-disease-related amyloido-
genic protein, RCMκ-CN, to determine whether
EGCG is a generic inhibitor of amyloid-fibril forma-
tion and to establish the mechanism by which this
inhibition occurs. We have previously shown that
RCMκ-CN fibril formation occurs through a unique
Fig. 6. EGCG protects against cell death by preventing
the formation of RCMκ-CN amyloid fibrils. MTT cell
survival assay of PC12 cells treated with RCMκ-CN pre-
incubated at 37 °C for 20 h in the presence and in the
absence of EGCG from the in situ ThT assay (see Fig. 1b).
The final concentration of RCMκ-CNwas 0.5 μM, and that
of EGCG was as indicated. Treatment with EGCG alone
did not affect cellular survival [filled circle data point
shows representative control treatment with EGCG (1 μM)
alone]. A sigmoidal logarithmic concentration–response
curve (variable slope model) is fitted for calculating the
EC50. Values represent mean±SEM (n=3). *Pb0.05 and
***Pb0.001 versus treatment with pre-incubated RCMκ-
CN alone (one-way repeated-measures ANOVA, Dun-
nett's post hoc test). Error bars are not visible when the
standard error is less than 1%.
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mechanism whereby the rate-limiting step is not a
typical nucleation event and rather the dissociation
of non-amyloidogenic micelle-like RCMκ-CN oligo-
mers into highly amyloidogenic RCMκ-CN mono-
mers.36 Energy-minimisation-based-modelling of
monomeric RCMκ-CN indicates that, although pre-
dominantly unfolded, the monomer can adopt a
‘horse-and-rider’ conformation that contains a large
hydrophobic and aromatic-rich sheet–turn–sheet
motif.39,40 The highly amyloidogenic nature of
RCMκ-CN is imputed to this constrained anti-
parallel β-sheet region since it requires little con-
formational change to aggregate and forms the cross-
β-sheet core of mature RCMκ-CN amyloid fibrils.36
Moreover, the RCMκ-CN aggregation cascade is
proposed to occur through the simple fibrillar
alignment and stacking of these well-positioned β-
sheet regions.36,40
Here, the coupled findings of ThT, TEM, DLS, CD
and real-time NMR experiments reveal that EGCG
prevents RCMκ-CN fibrillation by binding to and
stabilising RCMκ-CN in a native-like state with size,
morphology, conformation and flexibility similar to
those of native RCMκ-CN, which is incapable of
forming amyloid fibrils (Figs. 1, 3 and 5). The
inhibition is extremely efficient, with the IC50 for
RCMκ-CN (50 μM) fibril formation, as assessed by
ThT fluorescence, being 13±1 μM(Fig. 1b, inset). Our
results indicate that the stabilising action of EGCG
does not significantly modify the structure of the
RCMκ-CN species and that neither does it redirect
RCMκ-CN aggregation down the alternative dis-
ordered (amorphous) aggregation pathway. This is
in stark contrast to the action of EGCG toward α-
synuclein and amyloid-β, where EGCG redirects the
aggregation of these polypeptides down an off-
folding pathway, resulting in the formation of large
SDS-stable amorphous structures.34 This action is
akin to the behaviour we have observed for cha-
perone proteins, such asαB-crystallin,which redirect
α-synuclein from the fibril to the amorphous
aggregation pathway.51,52 Thus, while it appears
that EGCG is a generic inhibitor of fibril formation,
the mechanism by which it achieves this inhibition is
not generic—that is, the nature of the target poly-
peptide and itsmechanismof fibril formation play an
important role on the resulting effect of EGCG.
Current understanding of the non-covalent inter-
actions between amyloidogenic polypeptides and
EGCG (or other polyphenolics) is based primarily
on examination of the physicochemical properties
and structural similarities of polyphenols. It is
conjectured that polyphenols associate with amyloi-
dogenic sequences of fibril-forming proteins pre-
dominantly via a combination of (1) aromatic π–π
stacking interactions between the polyphenolic
rings and the aromatic residues common to most
amyloidogenic sequences, (2) hydrogen bonding to
the polypeptide main chain via the phenolic hydro-
xyls and (3) hydrophobic interactions owing to the
lipophilic nature of polyphenols and the inherent
hydrophobicity of amyloidogenic sequences.8,53–55
On interacting, polyphenols are thought to prevent
the β-strand/sheet formation and stacking events
necessary for fibrillation.8,54,55 This is achieved by
disrupting the hydrogen-bonding network of the β-
sheets, the side-chain π-π stacking within the core
amyloidogenic sequence and the inherent hydro-
phobic interactions that are believed to drive
aggregation by providing stability, directionality
and orientation for self-assembly.8,53–55 The data
presented here add support for these mechanistic
theories—that is, the NMR spectroscopy and NBT
staining experiments demonstrate that EGCG has a
high affinity for the constrained amyloidogenic β-
sheet structure of RCMκ-CN through strong SDS-
stable hydrophobic associations (Figs. 2 and 4).
Moreover, since over 85% of all the aromatic side
chains of RCMκ-CN reside within its fibril core (the
putative sheet–turn–sheet motif),36,40 it is likely that
π–π stacking interactions are also of importance. It is
worth noting that both BSA and RCMκ-CN bind
EGCG as monitored using the NBT-based assay
(Fig. 2). This is contrary to findings in the study by
Ehrnhoefer et al.,34 where EGCG was found to bind
urea-denatured BSA but not the untreated protein,
and it was speculated that the unfolding of poly-
peptide chains is a prerequisite for EGCG binding.
The poorer sensitivity of the NBT assay in the
Ehrnhoefer et al. study may account for the dis-
crepancy with our results.
Amyloid deposits are firmly linked with disease,
but the mechanisms by which the fibrillar entities
lead to cell death are largely unclear.1,2,56 For years,
it was postulated that the insoluble plaques of
amyloid fibrils were the most cytotoxic amyloido-
genic species (the amyloid hypothesis).1,56,57 How-
ever, recently, this hypothesis has been challenged
and there is much debate as to whether the soluble
pre-fibrillar intermediates in the typical aggregation
pathway are more cytotoxic than the insoluble
mature fibrils.1,58 For instance, there is strong
evidence that soluble amyloid-β dimers are the
dominant contributors to Alzheimer's disease
pathophysiology.58 Since an anti-aggregate, such
as EGCG, is likely to act at multiple steps along the
fibril-forming pathway, a concern is that these
inhibitors may block the aggregation process and
cause the build-up of the cytotoxic pre-fibrillar
oligomers, thereby exacerbating the problem. Here,
PC12 cell survival studies to assess the protective
potential of EGCG reveal that the attenuation of
RCMκ-CN fibril formation in vitro directly correlates
with protection from RCMκ-CN amyloid-induced
toxicity (Fig. 6). It is concluded that the primary
mechanism by which EGCG affords cytoprotection
is via suppression of RCMκ-CN aggregation. How-
ever, the known beneficial properties of polyphe-
nols, such as radical scavenging, reduction of
reactive oxidative species and/or chelating of
metal ions, may also contribute to the amelioration
of RCMκ-CN fibril-associated toxicity.8,15,24,55 More-
over, from the standpoint that EGCG constrains
RCMκ-CN in its native-like state, the data imply that
mature RCMκ-CN amyloid fibrils are more cyto-
toxic than their non-fibrillar counterparts. These
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data are consistent with our recent studies char-
acterising RCMκ-CN cytotoxicity (F.C.D. et al.,
unpublished results).
In all, the high efficacy of EGCG as a generic
anti-aggregate makes it an excellent candidate for
the design and synthesis of more potent fibrilla-
tion blockers. Synthesis of EGCG analogues (e.g.,
via combinatorial chemistry) may provide the
answer to its structure–activity relationship and
its greater potency over other anti-amyloidogenic
polyphenols.8,13,14,34 Moreover, analogues may be
the solution to the challenges of stability, bioavail-
ability and metabolic transformation that face the
development of green tea polyphenols as therapeu-
tic agents.46 Although EGCG was unable to act as a
β-sheet breaker (data not shown), the ability of
future anti-aggregates to disrupt and destroy pre-
formed amyloid fibrils, and thus reverse the fibrilla-
tion pathway, is an important goal. Overall, this
work confirms that small-molecule anti-aggregates
are an exciting therapeutic strategy for the treatment
of amyloidosis and that EGCG, in particular,
presents a promisingway forward in this endeavour.
Materials and Methods
Materials
Unless specified, all materials and reagents were of
analytical grade and obtained from the Sigma Chemical
Company (St. Louis,MO,USA). κ-Caseinwas reduced and
carboxymethylated as described by Shechter et al.,59 and
the lyophilised RCMκ-CN was stored at −20 °C until use.
Black μClear 96-microwell plates were supplied byGreiner
Bio-One (Stonehouse, UK), and Thin Seal self-adhesive
plate covers were purchased from Excel Scientific (Chi-
cago, IL, USA). Carbon-coated 400-mesh nickel TEM grids
were purchased from SPI Supplies (West Chester, PA,
USA), and uranyl acetate was bought from Agar Scientific
(Stansted, UK). Serum-free medium (RPMI 1640) powder,
foetal bovine serum, horse serum and L-glutamine were
supplied by Thermo Electron Corporation (Melbourne,
Australia). PC12 cells were donated by Prof. John Piletz
(University of Mississippi, Oxford, MS, USA). All buffers
were filtered using a 0.2-μm syringe filter before use.
Preparation of samples for assay
Unless stated otherwise, all solutions of protein or
EGCG and reaction mixtures of EGCG and protein were
prepared in sodium phosphate buffer (50 mM, pH 7.4) at
4 °C. For aggregationmixtures, separate solutions of native
protein and EGCG were first prepared at twice the
required concentration. These stocks were then combined
in equal volumes to give the desired molar ratio of protein
to EGCG (as indicated in each figure). The desired
concentration of native protein solution was achieved by
standard spectrophotometric methodology using a CARY
5000 UV-Vis-NIR spectrophotometer (Varian, Melbourne,
Australia) and molar extinction coefficients of 0.95 and
0.66 mL mg−1 cm−1 at 280 nm for RCMκ-CN and BSA,
respectively.60,61 Once prepared, samples were then used
immediately in assay or pre-incubated at 37 °C for 20 or
40 h (as indicated in each figure) to allow for the formation
of RCMκ-CN amyloid fibrils or inhibition thereof by
EGCG.
In situ thioflavin T fluorescence assay
ThT (10 μM) was added to 200-μL samples using a stock
ThT solution (200 μM) prepared in filtered sodium
phosphate buffer (50 mM, pH 7.4). The samples were
then incubated at 37 °C in black μClear 96-microwell
plates that were sealed to prevent evaporation. The ThT
fluorescence intensity of each sample was recorded every
5 min using a FLUOstar OPTIMA plate reader (BMG
Labtechnologies, Melbourne, Australia) with 440-/490-
nm excitation/emission filters set. Since native RCMκ-CN
binds some ThT due to its β-sheet content,40 the ThT data
were normalised by plotting the change in ThT fluores-
cence [arbitrary units (a.u.)], ΔF, as determined by the
following equation: ΔF=F−F30, where F is the mean ThT
fluorescence reading (a.u.) from triplicate experiments and
F30 is the mean ThT fluorescence reading (a.u.) after
30 min of incubation once all samples had evenly
equilibrated to 37 °C. The percentage of protection (%)
was calculated using the following equation: Percent
Protection= [1−ΔF30(RCMκ-CN+EGCG)/ΔF30(RCMκ-
CN)]×100, where ΔF30(RCMκ-CN+EGCG) is the mean
change in ThT fluorescence measurement (a.u.) at the
plateau phase for samples of RCMκ-CN treated with
EGCG and ΔF30(RCMκ-CN) is the mean change in ThT
fluorescence measurement (a.u.) for the control sample of
RCMκ-CN alone at the plateau phase. The presence of ThT
at the concentration used did not affect RCMκ-CN fibril
formation.37 EGCG is not spectroscopically active at the
wavelengths of ThT fluorescence and does not influence
the detected ThT fluorescence (data not shown).
Transmission electron microscopy
Two-microliter aliquots were taken from samples of the
ThT fluorescence assay before or after incubation (as
indicated in each figure) and transferred onto the surface
of carbon-coated 400-mesh nickel TEM grids. The grid
surface was then washed with 0.22-μm filtered MilliQ
water (3×10 μL) and negatively stained with uranyl
acetate solution (10 μL, 2% w/v, in MilliQ). Between each
wash and after staining, excess solution was removed by
absorbing with filter paper. The grid was left to air dry and
then viewed under magnification of 25,000×–64,000×
using a Philips CM100 transmission electron microscope
(Philips, Eindhoven, The Netherlands) with an 80-kV
excitation voltage.
Dynamic light scattering
Time-resolved DLS analysis was performed at 37 °C
using a Zetasizer Nano-ZS (Malvern Instruments, Wor-
cestershire, UK). Every 5 min, the particle diameter-
intensity distribution and mean hydrodynamic diameter
were determined from 13 acquired correllograms using
the program CONTIN62 and the method of cumulants,63
respectively, via the attached Dispersion Technology
Software (Malvern Instruments Ltd., Worcestershire, UK).
Nitroblue tetrazolium staining
NBT staining of proteins electroblotted onto 0.2-μm
polyvinylidene fluoride membrane was performed as
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described previously.34,42 The intensity of formazan
bound to each band was quantified using gel colorimetric
imaging analysis in ImageJ 1.40g software (Wayne
Rasband, National Institute of Health, MD, USA).
Circular dichroism spectroscopy
Far-UV CD spectra were recorded at 37 °C on a JASCO
J-815 CD spectropolarimeter (JASCO, Easton, MD, USA)
using a 0.1-cm path-length cuvette and a step of 0.1 nm, a
scan rate of 20 nm s−1, 4 s of delay and a scan average of
five. The acquired spectra were corrected for minor
solvent or EGCG contributions by subtracting the refer-
ence spectra of buffer or corresponding EGCG solution
without RCMκ-CN. The far-UV CD spectra of all samples
prior to incubation were identical (data not shown).
Solution-state 1H NMR spectroscopy
Samples were prepared as described above with the
exception that filtered sodium phosphate buffer (50 mM,
pH 7.4) was prepared using deuterium oxide in place of
MilliQ water. Samples were placed in separate 535-PP
NMR tubes (Wilmad, Buena, NJ, USA), and one-dimen-
sional 1H and two-dimensional TOCSY spectra were
acquired using a Varian UNITY Inova NMR spectrometer
(Varian, Palo Alto, CA, USA) equippedwith an Oxford 600
MHz magnet (Oxford, UK) and a pulse-field gradient 5-
mm probe. The spectrometer was operated at 600 MHz
with a sweep width of 7000.5 Hz and a relaxation delay of
1 s, and water signal suppression was achieved using a
PRESAT pulse sequence. Single spectra were recorded at
25 °C to prevent the formation of RCMκ-CN amyloid fibrils
over the period of spectral acquisition.37 For real-timeNMR
experiments, samples were incubated at 37 °C and spectra
were recorded every 5min. Each spectrum in the arraywas
processed equally, and the resonance decaywas calculated
as a percentage of the absolute resonance intensity at 0min.
Random noise was of the order of 10% and was reduced to
show overall trends using second-order Savitzky–Golay
smoothing (15 neighbours). All spectra were referenced to
the chemical shift of the HOD resonance and were
processed using VNMRJ 2.1b software (Varian).
Pheochromocytoma-12 cell culture and MTT assay
PC12 cells were grown in RPMI 1640 medium supple-
mented with 10% v/v horse serum, 5% v/v foetal bovine
serum, 10 U mL−1 of penicillin and 10 μg mL−1 of
streptomycin. Cells were cultured in uncoated 75-cm2
plastic flasks in an incubator with 95% air and 5% CO2 at
37 °C. The medium was refreshed every 2–3 days. For
treatment, cells fromculturewere seeded in 96-well plates at
a density of 2×104 cells per well in 100-μL full-serum
medium and then incubated for 24 h. The plated cells were
then treated (six replicates per treatment) by diluting the
incubated samples from the in situ ThT fluorescence assay
directly into the cell culture medium to give a final RCMκ-
CN concentration of 0.5 μM and/or the indicated concen-
trations of EGCG. The presence of residual ThT (0.1 μM)did
not affect cell survival (data not shown). Recent unpub-
lished work from our laboratory has shown that an RCMκ-
CN concentration of 0.5 μM ismost practicable for inducing
cell death (F.C.D. et al., unpublisheddata).Moreover, by first
allowing for the formation of amyloid fibrils or inhibition
thereof in a controlled environment in vitro, we avoid
interference by active molecular chaperones, such as
clusterin and BSA, which are readily present as nutrients
in cell medium.44,64,65 After incubation of the treated cells
for 48 h, the treatment mixture was removed and 100 μL of
serum-free medium containing MTT (0.6 mM) was added
to eachwell. The cells were then incubated for an additional
2 h, and the MTT-containing medium was replaced with
100 μL of DMSO. Formazan absorption was then measured
at 560 nm using a BMG Polarstar microplate reader (BMG
Labtechnologies, Offenburg, Germany). Mean absorption
readings from sextuplet wells were taken, and the
percentage of MTT reduction (%) for each treatment was
calculated using the following equation: MTT Reduc-
tion=A(treated)/A(untreated)×100, where A(treated) is
the mean formazan absorption reading for each treatment
and A(untreated) is the mean formazan absorption reading
for cells treated with phosphate buffer only.
Statistics, smoothing and curve fitting
All tests of statistical significance, smoothing functions
and curve fitting were performed using GraphPad PRISM
5.01 (GraphPad Software, San Diego, CA, USA).
Acknowledgements
This work was supported by a grant from the
Australian Research Council to J.A.C. H.E. was
supported by a National Health and Medical
Research Council Peter Doherty Australian Biome-
dical Fellowship. We thank Lyn Waterhouse (Ade-
laide Microscopy, The University of Adelaide) for
assisting with TEM and Phil Clements (School of
Chemistry & Physics, The University of Adelaide)
for assisting with the NMR experiments. We also
gratefully acknowledge Dr. Kristen Bremmell
(School of Pharmacy and Medical Sciences, Uni-
versity of South Australia) for helping with DLS
measurements and Dr. Deborah Tew (Department of
Pathology, The University of Melbourne) for kindly
helping with the CD experiments.
Supplementary Data
Supplementary data associated with this article
can be found, in the online version, at doi:10.1016/
j.jmb.2009.07.031
References
1. Chiti, F. & Dobson, C. M. (2006). Protein misfolding,
functional amyloid, and human disease. Annu. Rev.
Biochem. 75, 333–366.
2. Ecroyd, H. & Carver, J. A. (2008). Unraveling the
mysteries of protein folding and misfolding. IUBMB
Life, 60, 769–774.
3. Westermark, P., Benson, M. D., Buxbaum, J. N., Cohen,
A. S., Frangione, B., Ikeda, S. et al. (2005). Amyloid:
toward terminology clarification. Report from the
Nomenclature Committee of the International Society
of Amyloidosis. Amyloid, 12, 1–4.
698 Anti-Aggregation Activity of EGCG
4. Sacchettini, J. C. & Kelly, J. W. (2002). Therapeutic
strategies for human amyloid diseases. Nat. Rev. Drug
Discov. 1, 267–275.
5. Rochet, J. C. (2007). Novel therapeutic strategies for
the treatment of protein-misfolding diseases. Expert
Rev. Mol. Med. 9, 1–34.
6. Chaudhuri, T. K. & Paul, S. (2006). Protein-misfolding
diseases and chaperone-based therapeutic approaches.
FEBS J. 273, 1331–1349.
7. Sciarretta, K. L., Gordon, D. J. &Meredith, S. C. (2006).
Peptide-based inhibitors of amyloid assembly.Methods
Enzymol. 413, 273–312.
8. Porat, Y., Abramowitz, A. & Gazit, E. (2006). Inhibi-
tion of amyloid fibril formation by polyphenols:
structural similarity and aromatic interactions as a
common inhibition mechanism. Chem. Biol. Drug Des.
67, 27–37.
9. Yamin, G., Ono, K., Inayathullah, M. & Teplow, D. B.
(2008). Amyloid beta-protein assembly as a therapeu-
tic target of Alzheimer's disease. Curr. Pharm. Des. 14,
3231–3246.
10. Ono, K., Hirohata, M. & Yamada, M. (2008). Alpha-
synuclein assembly as a therapeutic target of Parkin-
son's disease and related disorders. Curr. Pharm. Des.
14, 3247–3266.
11. Barten, D. M. & Albright, C. F. (2008). Therapeutic
strategies for Alzheimer's disease. Mol. Neurobiol. 37,
171–186.
12. Dobson, C. M. (2006). Protein aggregation and its
consequences for human disease. Prot. Peptide Lett. 13,
219–227.
13. Riviere, C., Richard, T., Quentin, L., Krisa, S., Merillon,
J. M. & Monti, J. P. (2007). Inhibitory activity of
stilbenes on Alzheimer's beta-amyloid fibrils in vitro.
Bioorg. Med. Chem. 15, 1160–1167.
14. Kim, H., Park, B. S., Lee, K. G., Choi, C. Y., Jang, S. S.,
Kim, Y. H. & Lee, S. E. (2005). Effects of naturally
occurring compounds on fibril formation and oxida-
tive stress of beta-amyloid. J. Agric. Food Chem. 53,
8537–8541.
15. Chen, D., Milacic, V., Chen, M. S., Wan, S. B., Lam,
W.H., Huo, C. et al. (2008). Tea polyphenols, their
biological effects and potential molecular targets.
Histol. Histopathol. 23, 487–496.
16. Basu, A. & Lucas, E. A. (2007). Mechanisms and effects
of green tea on cardiovascular health. Nutr. Rev. 65,
361–375.
17. Moon, H. S., Lee, H. G., Choi, Y. J., Kim, T. G. & Cho,
C. S. (2007). Proposed mechanisms of (−)-epigalloca-
techin-3-gallate for anti-obesity. Chem.-Biol. Interact.
167, 85–98.
18. Tipoe, G. L., Leung, T. M., Hung, M. W. & Fung, M. L.
(2007). Green tea polyphenols as an anti-oxidant and
anti-inflammatory agent for cardiovascular protec-
tion. Cardiovasc. Hematol. Disord. Drug Targets, 7,
135–144.
19. Wolfram, S. (2007). Effects of green tea and EGCG on
cardiovascular and metabolic health. J. Am. Coll. Nutr.
26, 373S–388S.
20. Babu, P. V. & Liu, D. (2008). Green tea catechins and
cardiovascular health: an update. Curr. Med. Chem. 15,
1840–1850.
21. Khan, N. &Mukhtar, H. (2008). Multitargeted therapy
of cancer by green tea polyphenols. Cancer Lett. 269,
269–280.
22. Kim, J. A. (2008). Mechanisms underlying beneficial
health effects of tea catechins to improve insulin
resistance and endothelial dysfunction. Endocr. Metab.
Immune Disord. Drug Targets, 8, 82–88.
23. Yang, C. S., Ju, J., Lu, G., Xiao, H., Hao, X., Sang, S. &
Lambert, J. D. (2008). Cancer prevention by tea and tea
polyphenols. Asia Pac. J. Clin. Nutr. 17(Suppl. 1),
245–248.
24. Yang, C. S., Lambert, J. D. & Sang, S. (2009).
Antioxidative and anti-carcinogenic activities of tea
polyphenols. Arch. Toxicol. 83, 11–21.
25. Ono, K., Condron, M. M., Ho, L., Wang, J., Zhao, W.,
Pasinetti, G. M. & Teplow, D. B. (2008). Effects of grape
seed-derived polyphenols on amyloid beta-protein
self-assembly and cytotoxicity. J. Biol. Chem. 283,
32176–32187.
26. Rezai-Zadeh, K., Arendash, G. W., Hou, H., Fernan-
dez, F., Jensen, M., Runfeldt, M. et al. (2008). Green tea
epigallocatechin-3-gallate (EGCG) reduces beta-amy-
loid mediated cognitive impairment and modulates
tau pathology in Alzheimer transgenic mice. Brain
Res. 1214, 177–187.
27. Rasoolijazi, H., Joghataie, M. T., Roghani, M. &
Nobakht, M. (2007). The beneficial effect of (−)-
epigallocatechin-3-gallate in an experimental model
of Alzheimer's disease in rat: a behavioral analysis.
Iran. Biomed. J. 11, 237–243.
28. Lin, C. L., Chen, T. F., Chiu, M. J., Way, T. D. & Lin, J.K.
(2009). Epigallocatechin gallate (EGCG) suppresses
beta-amyloid-induced neurotoxicity through inhibit-
ing c-Abl/FE65 nuclear translocation and GSK3 beta
activation. Neurobiol. Aging, 30, 81–92.
29. Shimmyo, Y., Kihara, T., Akaike, A., Niidome, T. &
Sugimoto, H. (2008). Epigallocatechin-3-gallate and
curcumin suppress amyloid beta-induced beta-site
APP cleaving enzyme-1 upregulation. NeuroReport,
19, 1329–1333.
30. Mandel, S. A., Amit, T., Kalfon, L., Reznichenko, L.,
Weinreb, O. & Youdim, M. B. (2008). Cell signaling
pathways and iron chelation in the neurorestorative
activity of green tea polyphenols: special reference to
epigallocatechin gallate (EGCG). J. Alzheimer's Dis. 15,
211–222.
31. Avramovich-Tirosh, Y., Reznichenko, L., Mit, T.,
Zheng, H., Fridkin, M., Weinreb, O. et al. (2007).
Neurorescue activity, APP regulation and amyloid-
beta peptide reduction by novel multi-functional
brain permeable iron- chelating- antioxidants, M-30
and green tea polyphenol, EGCG. Curr. Alzheimer Res.
4, 403–411.
32. Choi, Y. T., Jung, C. H., Lee, S. R., Bae, J. H., Baek,
W.K., Suh, M. H. et al. (2001). The green tea
polyphenol (−)-epigallocatechin gallate attenuates
beta-amyloid-induced neurotoxicity in cultured hip-
pocampal neurons. Life Sci. 70, 603–614.
33. Reznichenko, L., Amit, T., Zheng, H., Avramovich-
Tirosh, Y., Youdim, M. B., Weinreb, O. & Mandel, S.
(2006). Reduction of iron-regulated amyloid precursor
protein and beta-amyloid peptide by (−)-epigalloca-
techin-3-gallate in cell cultures: implications for iron
chelation in Alzheimer's disease. J. Neurochem. 97,
527–536.
34. Ehrnhoefer, D. E., Bieschke, J., Boeddrich, A.,
Herbst, M., Masino, L., Lurz, R. et al. (2008).
EGCG redirects amyloidogenic polypeptides into
unstructured, off-pathway oligomers. Nat. Struct.
Mol. Biol. 15, 558–566.
35. Ehrnhoefer, D. E., Duennwald, M., Markovic, P.,
Wacker, J. L., Engemann, S., Roark, M. et al. (2006).
Green tea (−)-epigallocatechin-gallate modulates early
events in huntingtin misfolding and reduces toxicity
in Huntington's disease models. Hum. Mol. Genet. 15,
2743–2751.
699Anti-Aggregation Activity of EGCG
36. Ecroyd, H., Koudelka, T., Thorn, D. C., Williams,
D.M., Devlin, G., Hoffmann, P. & Carver, J. A. (2008).
Dissociation from the oligomeric state is the rate-
limiting step in fibril formation by kappa-casein.
J. Biol. Chem. 283, 9012–9022.
37. Thorn, D. C., Meehan, S., Sunde, M., Rekas, A., Gras,
S. L., MacPhee, C. E. et al. (2005). Amyloid fibril
formation by bovine milk kappa-casein and its
inhibition by the molecular chaperones alphaS- and
beta-casein. Biochemistry, 44, 17027–17036.
38. Vreeman, H. J., Brinkhuis, J. A. & van der Spek, C. A.
(1981). Some association properties of bovine SH-
kappa-casein. Biophys. Chem. 14, 185–193.
39. Kumosinski, T. F., Brown, E. M. & Farrell, H. M., Jr
(1993). Three-dimensional molecular modeling of
bovine caseins: a refined, energy-minimized kappa-
casein structure. J. Dairy Sci. 76, 2507–2520.
40. Farrell, H. M., Jr, Cooke, P. H., Wickham, E. D.,
Piotrowski, E. G. & Hoagland, P. D. (2003). Environ-
mental influences on bovine kappa-casein: reduction
and conversion to fibrillar (amyloid) structures.
J. Protein Chem. 22, 259–273.
41. Schmitz, K. S. (1990). Dynamic Light Scattering By
Macromolecules. Academic Press, Boston, MA.
42. Paz, M. A., Fluckiger, R., Boak, A., Kagan, H. M. &
Gallop, P. M. (1991). Specific detection of quinopro-
teins by redox-cycling staining. J. Biol. Chem. 266,
689–692.
43. Gutierrez, P. L. (2000). The metabolism of quinone-
containing alkylating agents: free radical production
and measurement. Front. Biosci. 5, D629–D638.
44. Marini, I., Moschini, R., Corso, A. D. & Mura, U.
(2005). Chaperone-like features of bovine serum
albumin: a comparison with alpha-crystallin. Cell.
Mol. Life Sci. 62, 3092–3099.
45. Zunszain, P. A., Ghuman, J., Komatsu, T., Tsuchida, E.
& Curry, S. (2003). Crystal structural analysis of
human serum albumin complexed with hemin and
fatty acid. BMC Struct. Biol. 3, 6.
46. Huo, C., Wan, S. B., Lam, W. H., Li, L., Wang, Z.,
Landis-Piwowar, K. R. et al. (2008). The challenge of
developing green tea polyphenols as therapeutic
agents. Inflammopharmacology, 16, 248–252.
47. Kajiya, K., Kumazawa, S., Naito, A. & Nakayama, T.
(2008). Solid-state NMR analysis of the orientation
and dynamics of epigallocatechin gallate, a green tea
polyphenol, incorporated into lipid bilayers. Magn.
Reson. Chem. 46, 174–177.
48. Feng, B. Y., Toyama, B. H., Wille, H., Colby, D. W.,
Collins, S. R., May, B. C. et al. (2008). Small-molecule
aggregates inhibit amyloid polymerization. Nat.
Chem. Biol. 4, 197–199.
49. Weber, K. & Osborn, M. (1969). The reliability of
molecular weight determinations by dodecyl sulfate-
polyacrylamide gel electrophoresis. J. Biol. Chem. 244,
4406–4412.
50. Meehan, S., Knowles, T. P., Baldwin, A. J., Smith, J. F.,
Squires, A. M., Clements, P. et al. (2007). Character-
isation of amyloid fibril formation by small heat-
shock chaperone proteins human alphaA-, alphaB-
and R120G alphaB-crystallins. J. Mol. Biol. 372,
470–484.
51. Rekas, A., Adda, C. G., Andrew Aquilina, J.,
Barnham, K. J., Sunde, M., Galatis, D. et al. (2004).
Interaction of the molecular chaperone alphaB-
crystallin with alpha-synuclein: effects on amyloid
fibril formation and chaperone activity. J. Mol. Biol.
340, 1167–1183.
52. Ecroyd, H. & Carver, J. A. (2009). Crystallin proteins
and amyloid fibrils. Cell. Mol. Life Sci. 66, 62–81.
53. Gazit, E. (2002). A possible role for pi-stacking in
the self-assembly of amyloid fibrils. FASEB J. 16,
77–83.
54. Gazit, E. (2005). Mechanisms of amyloid fibril self-
assembly and inhibition. Model short peptides as a
key research tool. FEBS J. 272, 5971–5978.
55. Shoval, H., Lichtenberg, D. & Gazit, E. (2007). The
molecular mechanisms of the anti-amyloid effects of
phenols. Amyloid, 14, 73–87.
56. Soto, C. & Estrada, L. D. (2008). Protein misfolding
and neurodegeneration. Arch. Neurol. 65, 184–189.
57. Stefani, M. & Dobson, C. M. (2003). Protein aggrega-
tion and aggregate toxicity: new insights into protein
folding, misfolding diseases and biological evolution.
J. Mol. Med. 81, 678–699.
58. Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A.,
Shepardson, N. E., Smith, I. et al. (2008). Amyloid-beta
protein dimers isolated directly from Alzheimer's
brains impair synaptic plasticity and memory. Nat.
Med. 14, 837–842.
59. Shechter, Y., Patchornik, A. & Burstein, Y. (1973).
Selective reduction of cystine I–VIII in alpha-lactalbu-
min of bovine milk. Biochemistry, 12, 3407–3413.
60. Fox, P. F. & McSweeney, P. L. H. (1998). Dairy
Chemistry and Biochemistry. Blackie Academic &
Professional, London, UK.
61. Peters, T., Jr. (1995). All About Albumin: Biochemistry,
Genetics, andMedical Applications.Academic Press Inc.,
San Diego, CA.
62. Provencher, S. W. (1982). CONTIN: a general purpose
constrained regularization program for inverting
noisy linear algebraic and integral equations. Comput.
Phys. Commun. 27, 229–242.
63. Koppel, D. E. (1972). Analysis of macromolecular
polydispersity in intensity correlation spectroscopy:
the method of cumulants. J. Chem. Phys. 57, 4814–4820.
64. Yerbury, J. J., Poon, S., Meehan, S., Thompson, B.,
Kumita, J. R., Dobson, C. M. & Wilson, M. R. (2007).
The extracellular chaperone clusterin influences amy-
loid formation and toxicity by interacting with
prefibrillar structures. FASEB J. 21, 2312–2322.
65. Maiti, T. K., Ghosh, K. S. & Dasgupta, S. (2006).
Interaction of (−)-epigallocatechin-3-gallate with
human serum albumin: fluorescence, Fourier trans-
form infrared, circular dichroism, and docking stu-
dies. Proteins, 64, 355–362.
700 Anti-Aggregation Activity of EGCG
